Editors choice: Benefits of Coffee Consumption for Human Health: An Overview

Author(s):Jéssica Petrine Castro Pereira*Fernanda Aparecida Castro Pereira and Carlos José Pimenta

Background: Coffee is one of the most consumed beverages worldwide and is popular for its characteristic flavor and rich organoleptic properties.

Aim: Based on published articles, the aims of this review are i) study the association between coffee consumption and benefits to human health; ii) the effects of coffee consumption on some pathologies; and iii) provide a description of coffee’s bioactive compounds.

Discussion: Coffee presents bioactive compounds, which include phenolic compounds, especially chlorogenic acid (caffeoylquinic acid), trigonelline, and diterpenes, such as cafestol and kahweol. These compounds are related to the beneficial effects for human health, including high antioxidant activity, antimutagenic activity, hepatoprotective action, reduced incidence of type 2 diabetes mellitus, reduced risk of cardiovascular diseases, decreased incidence of inflammatory diseases, reduced menopausal symptoms, and others. Coffee’s bioactive compounds are caffeine, chlorogenic acid, trigonelline, cafestol and kahweol, which are closely related to coffee’s beneficial effects.

Conclusion: The present review clarified that the benefits of moderate coffee consumption outweigh the associated risks.

Read more: http://bit.ly/3TVR51G

Most Cited Article – CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment

Author(s): Elifcan GezerMehtap CevikCansu Selcan AkdenizIsmail Polat CanbolatSelen YurdakulMurat SunbulPenbe CagatayGokce DeliormanAtila KaraalpCavlan Ciftci and Belgin Susleyici*


Objective: Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide and statins are frequently prescribed in the treatment of CAD to help lower blood cholesterol levels. Since the main enzyme involved in the metabolism of statins is CYP3A4, we aimed to investigate the effect of CYP3A4 * 1B genotypes on plasma lipid profile in Turkish cardiovascular disease subjects with and without obesity taking statin.

Materials and Methods: The study group consisted of 85 cardiovascular disease patients who were prescribed statins and had routine biochemical analysis data. Polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) assay was performed for genotyping of CYP3A4 *1B (rs2740574) polymorphism.

Results: Genotype distribution of CYP3A4 *1B polymorphism was found for homozygous wild (AA) and homozygous polymorphic (GG) genotypes as 94.1% and 5.9%, respectively. We did not detect patients with heterozygous genotype in our study group. We found that the mean LDL-c, TG and TC levels were higher in patients with CYP3A4 *1B GG compared to the AA genotype. The frequency of CYP3A4 *1B GG genotype frequency (9.5%) was detected higher in the obese patients compared to the non-obese patients (7.7%) (χ2=0.037, p=0.85).

Conclusion: Our results demonstrate that CYP3A4 *1B homozygous polymorphic genotype distribution tends to be higher in obese patients compared to non-obese patients with cardiovascular disease which may point to *1B allele having a slight effect on serum lipids during statin therapy. Additional studies with higher samples are needed for evaluating the role of CYP3A4 *1B on lipids in patients under statin therapy. Read now: https://bit.ly/3R8Bs6X

Press Release | Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases


Cardiovascular diseases (CVDs) are proven to be the leading cause of deaths throughout the world. If statistics are reviewed, almost four out of five deaths are due to myocardial infarction or stroke. Efforts to prevent CVD have little effect on the decrease of the number of CVD related deaths despite many medical advances. Therefore, the search for new and even better therapies and treatments for the betterment of those who are suffering from CVD is still in progress. The field of metabolomics has offered a good solution for these diseases. Metabolomic biomarkers help clinicians to identify the risk of CVD and take preventive measures before the diseases can surface. Early diagnosis of CVD is a good sign for a patient’s recovery and also for their health. Therefore, there is a need to establish reliable, sensitive and non-invasive biomarkers which can serve as therapeutic targets for prevention and treatment of CVD.

In this study, analytical techniques are discussed along with the workflow that is used in untargeted metabolomics. Case studies that highlight the use of untargeted metabolomics in CVD research are also identified. Five of the case studies show approaches to identify untargeted metabolomics and apply this information in clinical situations. Analysis was conducted for the prediction of cardiovascular disease risk, myocardial ischemia, transient ischemic attack, incident coronary heart disease, and myocardial infarction risk. The use of the untargeted metabolomics for risk assessment is still relatively new and there is still a need for future advancements in metabolomics technologies. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2018-12/bsp-nb122518.php



The article by Dr. Geoff H. Werstuck et al. is published in Cardiovascular & Hematological Disorders-Drug Targets, Volume 18, Issue 3, 2018. To obtain this article, please visit: http://www.eurekaselect.com/161468

CALL FOR PAPERS | Thematic Issue for Current Pharmaceutical Design

Journal: Current Pharmaceutical Design

Guest Editor(s): Ling-Qing Yuan
Tentative Publication Date: August, 2019


“Novel Strategies for Gene Therapy – Recent Advances in the use of Exosomes for Disease Treatment“

The aim of the present special issue is to invite researchers to contribute review or original research articles reporting the most recent and future therapeutic applications using exosomes in various diseases. Moreover, articles on the synthesis and isolation of exosomes, involvement of exosomes in the pathogenesis of different disease, and the use of exosomes in therapeutic strategies for different diseases are welcome. The objective and critical vision of this advance will be beneficial for us to understand and become familiar with the application of exosomes in treating different diseases. For more details please visit: https://bit.ly/2Je21qG


Email here to submit your paper: hermain@benthamscience.net

                                                          CC: faizan@benthamscience.net


cpd thematic flyers.jpg

CALL FOR PAPERS | Thematic Issue for Current Pharmaceutical Design

Journal: Current Pharmaceutical Design


Novel Strategies for Gene Therapy – Recent Advances in the use of Exosomes for Disease Treatment


The aim of the present special issue is to invite researchers to contribute review or original research articles reporting the most recent and future therapeutic applications using exosomes in various diseases. Moreover, articles on the synthesis and isolation of exosomes, involvement of exosomes in the pathogenesis of different disease, and the use of exosomes in therapeutic strategies for different diseases are welcome. The objective and critical vision of this advance will be beneficial for us to understand and become familiar with the application of exosomes in treating different diseases. For more details please visit: https://bit.ly/2Je21qG


Guest Editor(s): Ling-Qing Yuan
Tentative Publication Date: August, 2019

Email here to submit your paper:  faizan@benthamscience.net

                     CC: hermain@benthamscience.net 


cpd thematic flyers



Bentham Science Media Partnership | 7th World Heart Congress

Theme: Life Isn’t Measured in Minutes but in Heartbeats




Cardiology Congress 2019 Conference will be an investigation of new research Innovation in the field of Cardiology and spread the most recent advancements in heart disease prevention and rehabilitation. Argument on new technology enhancement in the field of Cardiovascular Disease and current practices in cardiovascular therapy, Cardiac progenitor cells, Hypertension for the primary care clinician, Stent procedure, Balloon Valvuloplasty, Coronary thrombectomy, Noninvasive cardiac imagingHeart failure, Congestive heart failure, Sports Cardiology and more. Differentiating heart disease and other cardiac conditions constitute a team of healthcare professionals, of which the Cardiology technologist is a key player.

This conference will provide a comprehensive update on all medical, surgical, interventional, and electrophysiological topics in cardiology and also provides the opportunity for clinicians, scientists, doctors and researchers from all over the world to gather and learn the latest advances in the field of cardiology and healthcare and to exchange scientific ideas and experiences in a distinctive environment.


Learn more about the conference at: https://heart.insightconferences.com/

Article by Disease |Study about How A Sample of Portuguese People Perceive the Health Benefits of Dietary Fibre

Bentham Oncology Collection | Oncology | Bowel Cancer


Graphical Abstract:



Background: Dietary Fibre (DF) has been part of human diet since ever, and its benefits for the human health have been well established and scientifically confirmed. However, it is important to study to what extent people are aware of those benefits.

Objective: Having in mind the importance of DF the present work was undertaken to study the level of knowledge of people residing in Portugal about the health effects related to DF.

Methods: A descriptive cross-sectional study was undertaken on a non-probabilistic sample of 382 adult participants. Descriptive statistics were used together with some inferential tests, all using the software SPSS and considering a level of significance of 5%.
Results: The results allowed concluding that people were differently informed about the effects of DF in preventing and/or treating various diseases, being constipation the most recognized, followed in decreasing order by obesity, bowel cancer, cholesterol, cardiovascular diseases, diabetes and breast cancer. The results also showed that significant differences were encountered between age groups for most of the diseases evaluated, but not between genders, levels of education or living environments.
Conclusion: Generally, it was concluded that the participants in this study were relatively well informed about the roles of DF in preventing and/or treating several diseases.

Read out more at: http://www.eurekaselect.com/node/149164/article

MOST ACCESSED ARTICLE – Novel Drug Targets for the Treatment of Cardiac Diseases – Current Pharmacogenomics and Personalized Medicine

Journal: Current Pharmacogenomics and Personalized Medicine

Author(s):  Marine Pingeon, Bruno Charlier, Federica De Lise, Francesca Mensitieri, Fabrizio Dal Piaz, Viviana Izzo*

Graphical Abstract:



Background: Cardiovascular disease is the leading cause of morbidity and mortality worldwide in developed countries, and its social and economic burden is expected to increase dramatically over the next decades. Despite significative improvement in the pharmacological treatment, and the huge advances in prevention, the quest for new molecular targets and for novel, more efficient and personalized therapies is still a priority for this group of pathologies.

Objective: The paramount complexity of the metabolic networks responsible for the onset and progression of cardiovascular disease is highlighted by the wide and diverse array of new molecular targets recently described in literature. In this brief review, we focused our interest on a subset of promising molecular targets for the development of new pharmacological treatments specific for cardiac diseases such as coronary artery disease, heart failure and myocardial infarction.

Conclusion: The global quest for new molecular targets for the treatment of cardiac diseases is leading to an impressive amount of records in the more recent literature. Although several promising molecular pathways have been identified so far, great caution should be used in considering all these targets effective in promoting the production of new drugs. The identification of suitable therapeutic targets is in fact an ongoing challenge that often lacks enough pre-clinical and clinical studies, which hinders the effective utilization of several new drugs due to a lack of efficacy or induction of safety liabilities.


OPEN ACCESS ARTICLE – Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer – Current Neurovascular Research

Journal: Current Neurovascular Research

Author(s):  Kenneth Maiese


Background: The mammalian circadian clock and its associated clock genes are increasingly been recognized as critical components for a number of physiological and disease processes that extend beyond hormone release, thermal regulation, and sleep-wake cycles. New evidence suggests that clinical behavior disruptions that involve prolonged shift work and even space travel may negatively impact circadian rhythm and lead to multi-system disease.

Methods: In light of the significant role circadian rhythm can hold over the body’s normal physiology as well as disease processes, we examined and discussed the impact circadian rhythm and clock genes hold over lifespan, neurodegenerative disorders, and tumorigenesis.

Results: In experimental models, lifespan is significantly reduced with the introduction of arrhythmic mutants and leads to an increase in oxidative stress exposure. Interestingly, patients with Alzheimer’s disease and Parkinson’s disease may suffer disease onset or progression as a result of alterations in the DNA methylation of clock genes as well as prolonged pharmacological treatment for these disorders that may lead to impairment of circadian rhythm function. Tumorigenesis also can occur with the loss of a maintained circadian rhythm and lead to an increased risk for nasopharyngeal carcinoma, breast cancer, and metastatic colorectal cancer. Interestingly, the circadian clock system relies upon the regulation of the critical pathways of autophagy, the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), and silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1) as well as proliferative mechanisms that involve the wingless pathway of Wnt/β-catenin pathway to foster cell survival during injury and block tumor cell growth.

Conclusion: Future targeting of the pathways of autophagy, mTOR, SIRT1, and Wnt that control mammalian circadian rhythm may hold the key for the development of novel and effective therapies against aging- related disorders, neurodegenerative disease, and tumorigenesis.

Read more here: http://www.eurekaselect.com/154252

MOST ACCESSED ARTICLE – Potential Role of Endothelin in Early Vascular Aging – Current Hypertension Reviews

Journal: Current Hypertension Reviews

Author(s): Michelle Trindade, Wille Oigman, Mario Fritsch Neves

Graphical Abstract:



Early vascular aging is a process associated with gradual alterations in the vessels, regarding their structure and function, taking a more rapid course than normal biological aging in the arteries. In the presence of cardiovascular disease, these age-associated alterations are accelerated, contributing in the appearance or the progression of cardiovascular disease, such as high blood pressure, dyslipidemia, smoking and diabetes. Endothelin-1 (ET-1) is the most abundant and important endothelin produced by vascular cells. ET-1 exerts its biological actions through the activation of two receptors: ETA and ETB. Many important functions are mediated by the activation of these receptors, such as cardiovascular remodeling, vasoconstriction, cell proliferation and differentiation, production of extracellular matrix, and water and sodium secretion control. ETA receptor seems to participate in the pathogenesis and development of diseases, such as diabetes, atherosclerosis, systemic and pulmonary hypertension, and cardiac remodeling after myocardial ischemia, whereas ETB receptor seems to prevent the overstimulation of ETA receptor, acting as a clearance receptor. Increased ET-1 system activity may contribute to vascular dysfunction in aging via multiple pathways, such as direct hemodynamic effects, vascular oxidative stress, inflammatory activity, mitogenic stimulation of the vascular smooth muscle cells and fibrotic processes. Endothelin receptor antagonists were considered to be used for the treatment of some diseases like hypertension, diabetes and chronic kidney disease. However, besides pulmonary hypertension, this class is not in clinical use because of the side effects and the availability of safer drugs for the treatment of these diseases.

To access the article, please visit: http://www.eurekaselect.com/151634


%d bloggers like this: